Pharmacological therapy in progressive supranuclear palsy

Archives of Neurology

Volumn 55, Issue 8, 1998, Pages 1099-1102

  Kompoliti, K ^a   Goetz, C G ^a   Litvan, Irene ^b   Jellinger, K ^c   Verny, M ^d  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d HÔPITAL CHARLES FOIX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMANTADINE; AMITRIPTYLINE; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; METHYSERGIDE MALEATE; MIANSERIN; NEUROTRANSMITTER; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; AUTOPSY; CLINICAL ARTICLE; DELUSION; DYSKINESIA; GASTROINTESTINAL TOXICITY; GAZE PARALYSIS; HALLUCINATION; HUMAN; MEDICAL RECORD; MOTOR DYSFUNCTION; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; TREATMENT OUTCOME; VERTIGO;

5-HYDROXYTRYPTOPHAN; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPARKINSON AGENTS; AUTOPSY; CHOLINERGIC ANTAGONISTS; FEMALE; HUMANS; MALE; METHYSERGIDE; MIDDLE AGED; SEROTONIN ANTAGONISTS; SUPRANUCLEAR PALSY, PROGRESSIVE; TREATMENT FAILURE;

EID: 0031846118     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.55.8.1099     Document Type: Article

References (31)

1. Levy R, Ruberg M, Herrero MT, et al. Alterations of GABAergic neurons in the basal ganglia of patients with progressive supranuclear palsy: an in situ hybridization study of GAD67 messenger RNA. Neurology. 1995;45:127-134.
2. Agid Y, Javoy-Agid F, Ruberg M, et al. Progressive supranuclear palsy: anatomoclinical and biochemical considerations. Adv Neurol. 1987;45:191-206.
3. Neophytides A, Lieberman AN, Goldstein M, et al. The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1982;45:261-263.
4. Rafal RD, Grimm RJ. Progressive supranuclear palsy: functional analysis of the response to methysergide and antiparkinsonian agents. Neurology. 1981;31: 1507-1518.
5. Jankovic J. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy. Neurology. 1983;33:505-507.
6. Haldeman S, Goldman JW, Hyde J, Pribram HF. Progressive supranuclear palsy, computed tomography, and response to antiparkinsonian drugs. Neurology. 1981; 31:442-445.
7. Kertzman C, Robinson DL, Litvan I. Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. Arch Neurol. 1990;47:1346-1350.
8. Blin J, Mazetti P, Mazoyer B, et al. Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy? Brain. 1995;118:1485-1495.
9. Litvan I, Blesa R, Clark K, et al. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Ann Neurol. 1994;36:55-61.
10. Litvan I. Cholinergic approaches to the treatment of progressive supranuclear palsy. J Neural Transm Suppl. 1994;42:275-281.
11. Litvan I, Gomez C, Atack JR, et al. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol. 1989;26:404-407.
12. Foster NL, Aldrich MS, Bluemlein L, White RF, Berent S. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology. 1989;39:257-261.
13. Newman GC. Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology. 1985;35:1189-1193.
14. Schneider LS, Gleason RP, Chui HC. Progressive supranuclear palsy with agitation: response to trazodone but not to thiothixine or carbamazepine. J Geriatr Psychiatry Neurol. 1989;2:109-1125.
15. Ghika J, Tennis M, Hoffman E, Schoenfeld D, Growdon J. Idazoxan treatment in progressive supranuclear palsy. Neurology. 1991;41:986-991.
16. Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol. 1996;55:97-105.
17. Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994;44:2015-2019.
18. Polo KB, Jabbari B. Botulinum toxin-A improves the rigidity of progressive supranuclear palsy. Ann Neurol. 1994;35:237-239.
19. Lepore V, Defazio G, Acquistapace D, et al. Botulinum A toxin for the so-called apraxia of lid opening. Mov Disord. 1995;10:525-526.
20. Barclay CL, Duff J, Sandor P, Lang AE. Limited usefulness of electroconvulsive therapy in progressive supranuclear palsy. Neurology. 1996;46:1284-1286.
21. Hauser RA, Trehan R. Initial experience with electroconvulsive therapy for progressive supranuclear palsy. Mov Disord. 1994;9:467-469.
22. Sandyk R, Iacono RP. Naloxone ameliorates presyncopal sensations in progressive supranuclear palsy. Int J Neurosci. 1987;35:89-90.
23. Gordon MF, Diaz-Olivo R, Hunt AL, Fahn S. Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders. Mov Disord. 1993;8:484-488.
24. Litvan I, Chase TN. Traditional and experimental therapeutic approaches. In: Litvan I, Agid Y, eds. Progressive Supranuclear Palsy: Clinical and Research Approaches. New York, NY: Oxford University Press Inc; 1992:254-269.
25. Bugiani O, Mancardi GL, Brusa A, Ederli A. The fine structure of subcortical neurofibrillary tangles in progressive supranuclear palsy. Acta Neuropathol (Berl). 1979;45:147-152.
26. Jellinger K. Progressive supranuclear palsy (subcortical argyrophilic dystrophy). Acta Neuropathol (Berl). 1971;19:347-352.
27. Jellinger K, Riederer P, Tomonaga M. Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm Suppl. 1980;(suppl 16):111-128.
28. Kish SJ, Chang LJ, Mirchandani L, Shannak K, Hornykiewicz O. Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol. 1985;18:530-536.
29. Litvan I, Agid Y, Jankovic J, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology. 1996;46:922-930.
30. Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol. 1993;16:338-346.
31. Collins SJ, Ahlskog JE, Parisi JE, Maraganore DM. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J Neurol Neurosurg Psychiatry. 1995;58:167-173.